Circulating Tumor DNA in Cancer Management

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Molecular techniques are increasingly vital in cancer patient management.
• Circulating tumor DNA (ctDNA), found in patient plasma, acts as a non-invasive liquid biopsy.
• ctDNA may represent the entire tumor genome, offering a comprehensive view.

Purpose of the Study:

• To explore the utility of ctDNA in cancer care.
• To highlight ctDNA's potential in guiding treatment decisions.
• To discuss ctDNA's role in monitoring disease and resistance.

Main Methods:

• Analysis of circulating tumor DNA (ctDNA) in patient plasma.
• Utilizing ctDNA as a surrogate for tumor genome analysis.
• Monitoring disease prognosis, progression, and molecular resistance via ctDNA.

Main Results:

• ctDNA can be identified in the plasma of cancer patients.
• ctDNA serves as a potential surrogate for the entire tumor genome.
• ctDNA aids in determining prognosis, monitoring progression, resistance, and heterogeneity.

Conclusions:

• ctDNA analysis is a promising tool for personalized cancer medicine.
• Further development of clinical standards is necessary for ctDNA validation.
• Improving reproducibility and accuracy will enhance ctDNA's clinical utility.